{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:46Z","timestamp":1792787806230,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Amgen AB, Sweden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0659-2","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T08:19:31Z","timestamp":1502871571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-2062","authenticated-orcid":false,"given":"Gunilla","family":"Journath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Hambraeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billie","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"L\u00f6thgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,16]]},"reference":[{"key":"659_CR1","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality, and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.","journal-title":"PLoS Med"},{"key":"659_CR2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","volume":"30","author":"L Bjorck","year":"2009","unstructured":"Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J. 2009;30:1046\u201356.","journal-title":"Eur Heart J"},{"key":"659_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)62027-3","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists CTT, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"659_CR4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/clpt.2014.86","volume":"96","author":"S Zoungas","year":"2014","unstructured":"Zoungas S, Curtis AJ, McNeil JJ, Tonkin AM. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins? Clin Pharmacol Ther. 2014;96:192\u2013205.","journal-title":"Clin Pharmacol Ther"},{"key":"659_CR5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","volume":"128","author":"SM Boekholdt","year":"2013","unstructured":"Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504\u201312.","journal-title":"Circulation"},{"key":"659_CR6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists CTT, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"659_CR7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635\u2013701.","journal-title":"Eur Heart J"},{"key":"659_CR8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129:S1\u201345.","journal-title":"Circulation"},{"key":"659_CR9","unstructured":"Medical product Agency. To prevent atherosclerotic cardiovascular disease with drugs- treatment recommendation. https:\/\/lakemedelsverket.se\/upload\/om-lakemedelsverket\/publikationer\/information-franlakemedelsverket\/2014\/Information_fran_lakemedelsverket_nr_5_2014_webb.pdf . Accessed 16 Oct 2016."},{"key":"659_CR10","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","volume":"31","author":"KA Fox","year":"2010","unstructured":"Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study). Eur Heart J. 2010;31:2755\u201364.","journal-title":"Eur Heart J"},{"key":"659_CR11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehm020","volume":"28","author":"P Lindgren","year":"2007","unstructured":"Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B, Investigators IT. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007;28:1448\u201353.","journal-title":"Eur Heart J"},{"key":"659_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CEOR.S26621","volume":"4","author":"SK Gandhi","year":"2012","unstructured":"Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulsson T. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. ClinicoEconomics and outcomes research : CEOR. 2012;4:1\u201311.","journal-title":"ClinicoEconomics and outcomes research : CEOR"},{"key":"659_CR13","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","volume":"96","author":"T Jernberg","year":"2010","unstructured":"Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617\u201321.","journal-title":"Heart"},{"key":"659_CR14","unstructured":"SWEDEHEART (2014). Annual report 2013. http:\/\/www.ucr.uu.se\/swedeheart\/ . Accessed 16 Oct 2016."},{"key":"659_CR15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PW Wilson","year":"2012","unstructured":"Wilson PW, D'Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695\u2013703.","journal-title":"Am J Med"},{"key":"659_CR16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163\u201370.","journal-title":"Eur Heart J"},{"key":"659_CR17","first-page":"21","volume":"12","author":"R Ara","year":"2008","unstructured":"Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess. 2008;12:21.","journal-title":"Health Technol Assess"},{"key":"659_CR18","doi-asserted-by":"publisher","unstructured":"Hallberg S, Gandra SR, Fox KM, et al. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. Eur J Health Econ. 2015; doi: 10.1007\/s10198-015-0702-0 .","DOI":"10.1007\/s10198-015-0702-0"},{"key":"659_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13060","volume":"13","author":"R Ara","year":"2009","unstructured":"Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1\u201374. 5-118","journal-title":"Health Technol Assess"},{"key":"659_CR20","unstructured":"Steen-Karlsson K, and Persson U. (2012) Kostnader f\u00f6r Hj\u00e4rt-K\u00e4rlsjukdom \u00e5r 2010 IHE Rapport Lund: Institutet f\u00f6r H\u00e4lso- och Sjukv\u00e5rdsekonomi."},{"key":"659_CR21","doi-asserted-by":"crossref","unstructured":"Danese M LM, Villa G, Lindgren P, van Hout B, and Taylor B. Differences between observed and predicted cardiovascular event rates using standard tools for risk prediction. The case of high-intensity statin users in the United Kingdom. Circulation 2015; 132: A18114 2015.","DOI":"10.1161\/circ.132.suppl_3.18114"},{"key":"659_CR22","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1093\/eurheartj\/eht159","volume":"34","author":"M Nichols","year":"2013","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J. 2013;34:3017\u201327.","journal-title":"Eur Heart J"},{"key":"659_CR23","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/eurheartj\/eht356","volume":"34","author":"M Nichols","year":"2013","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34:3028\u201334.","journal-title":"Eur Heart J"},{"key":"659_CR24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636\u201348.","journal-title":"Eur J Prev Cardiol"},{"key":"659_CR25","unstructured":"SWEDEHEART (2017). Annual report 2016. http:\/\/www.ucr.uu.se\/swedeheart\/dokument-sh\/arsrapporter . Accessed 2 March 2017."},{"key":"659_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.healthpol.2011.10.010","volume":"104","author":"B Pettersson","year":"2012","unstructured":"Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health policy. 2012;104:84\u201391.","journal-title":"Health policy"},{"key":"659_CR27","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1185\/03007990802203279","volume":"24","author":"JM Foody","year":"2008","unstructured":"Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin. 2008;24:1987\u20132000.","journal-title":"Curr Med Res Opin"},{"key":"659_CR28","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","volume":"166","author":"PM Ho","year":"2006","unstructured":"Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842\u20137.","journal-title":"Arch Intern Med"},{"key":"659_CR29","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","volume":"119","author":"PM Ho","year":"2009","unstructured":"Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028\u201335.","journal-title":"Circulation"},{"key":"659_CR30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1011180018244","volume":"23","author":"U Persson","year":"2001","unstructured":"Persson U, Norinder A, Hjalte K, Gralen K. The value of a statistical life in transport: findings from a new contingent valuation study in Sweden. J Risk Uncertainty. 2001;23:121\u201334.","journal-title":"J Risk Uncertainty"},{"issue":"43","key":"659_CR31","first-page":"3436","volume":"100","author":"U Persson","year":"2003","unstructured":"Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Lakartidningen. 2003;100(43):3436\u20137.","journal-title":"Lakartidningen"},{"key":"659_CR32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"659_CR33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"659_CR34","unstructured":"SWEDEHEART. http:\/\/www.ucr.uu.se\/swedeheart\/ . Accessed 3 August 2017."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T03:19:14Z","timestamp":1659323954000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0659-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0659-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,16]]},"article-number":"224"}}